What Is Craniopharyngioma? Symptoms, Diagnosis, and Treatment Options

Craniopharyngioma is a rare intracranial tumor. Although most cases are benign, the tumor develops close to critical structures such as the pituitary gland, hypothalamus, and optic nerves. Even a relatively small tumor can cause headaches, vision loss, endocrine disorders, growth delays, and other complications that may significantly affect a patient's quality of life.

So, what is craniopharyngioma? What are its typical symptoms? How is it diagnosed? What treatment options are currently available? What are the latest advances in treatment?

In this article, Hong Kong DengYueMed provides a comprehensive overview to help patients and caregivers better understand the disease and current treatment strategies.

What Is Craniopharyngioma?

Craniopharyngioma is a rare intracranial tumor that arises from embryonic remnants of the craniopharyngeal duct (Rathke's pouch). It most commonly occurs in the sellar and suprasellar regions of the brain.

According to the World Health Organization (WHO) Classification of Central Nervous System Tumors, the vast majority of craniopharyngiomas are classified as WHO Grade 1 tumors, meaning they are histologically benign. However, "benign" does not necessarily mean harmless.

Because these tumors are located near the pituitary gland, hypothalamus, optic nerves, and major cerebral blood vessels, even slow-growing lesions can compress surrounding tissues and lead to visual impairment, endocrine dysfunction, hypothalamic dysfunction, and neurological symptoms.

As a result, craniopharyngioma typically requires evaluation and treatment by a multidisciplinary team (MDT), including specialists in neurosurgery, endocrinology, radiation oncology, and ophthalmology.

Craniopharyngioma can occur at any age, with two peak incidence periods: children and adolescents (5–14 years old) and adults aged 50–70 years. It is one of the most common tumors in the sellar region in children and an important condition encountered in adult neurosurgery.

What Are the Types of Craniopharyngioma?

Based on histological characteristics, craniopharyngiomas are classified into two main subtypes.

Adamantinomatous Craniopharyngioma (ACP)

ACP accounts for the majority of all craniopharyngioma cases. It is more common in children but can also occur in adults.

Its characteristics include:

● Mixed cystic and solid components

● Frequent calcification

● Greater tendency to invade surrounding brain tissue

● Higher risk of recurrence

Current research suggests that ACP is closely associated with CTNNB1 gene mutations and abnormalities in the Wnt/β-catenin signaling pathway.

Papillary Craniopharyngioma (PCP)

PCP occurs almost exclusively in adults and typically has the following characteristics:

● Predominantly solid tumors

● Less calcification

● Relatively well-defined borders

● Generally easier to remove surgically

Notably, more than 90% of papillary craniopharyngiomas harbor the BRAF V600E mutation. This discovery has driven the development of BRAF/MEK-targeted therapy, providing a new treatment option for selected patients.

What Are the Symptoms of Craniopharyngioma?

Because the tumor develops near critical brain structures, symptoms vary among patients and may include the following.

1. Headache

As the tumor enlarges, increased intracranial pressure may cause persistent or recurrent headaches. Some patients may also experience nausea and vomiting.

2. Vision Loss or Visual Field Defects

When the tumor compresses the optic nerves or optic chiasm, symptoms may include:

● Decreased visual acuity

● Narrowing of the visual field

● Bitemporal hemianopia

● Blindness in severe cases

Therefore, ophthalmologic evaluation is an important part of the diagnostic workup.

3. Endocrine Disorders

Compression of the pituitary gland and hypothalamus may result in:

● Growth hormone deficiency

● Sex hormone deficiency

● Menstrual irregularities

● Infertility

● Hypothyroidism

● Adrenal insufficiency

● Diabetes insipidus

In children, additional manifestations may include short stature, growth retardation, or delayed puberty.

4. Hypothalamic Dysfunction

Some patients may develop:

● Obesity

● Excessive daytime sleepiness

● Mood changes

● Memory impairment

● Abnormal body temperature regulation

● Changes in appetite

These symptoms can significantly affect long-term quality of life.

How Is Craniopharyngioma Diagnosed?

The diagnosis of craniopharyngioma is based on clinical presentation, imaging studies, and pathological findings.

MRI Examination

Magnetic resonance imaging (MRI) is the most important imaging modality for diagnosing craniopharyngioma. It clearly demonstrates:

● Tumor size

● Cystic and solid components

● Relationship to the pituitary gland, optic nerves, and cerebral blood vessels

● Whether the hypothalamus is involved

MRI is also an essential tool for preoperative planning and postoperative follow-up.

CT Scan

Computed tomography (CT) is particularly useful for detecting tumor calcification, especially in patients with adamantinomatous craniopharyngioma.

Pathological Examination

A definitive diagnosis requires pathological examination to determine the tumor subtype.

Molecular Testing

For patients suspected of having papillary craniopharyngioma, BRAF V600E mutation testing may be recommended. The results can help confirm the subtype and guide subsequent treatment decisions.

What Are the Treatment Options for Craniopharyngioma?

Treatment is typically planned by a multidisciplinary team (MDT), including neurosurgeons, radiation oncologists, endocrinologists, ophthalmologists, and radiologists, to develop an individualized treatment strategy.

Surgery

Surgery remains the primary treatment for most patients.

Depending on the tumor's location, size, and relationship to surrounding structures, surgical approaches may include:

● Endoscopic endonasal surgery

● Microsurgical craniotomy

In recent years, the treatment strategy has shifted from pursuing complete tumor removal to achieving maximal safe resection, aiming to reduce neurological injury and endocrine complications.

Radiation Therapy

Radiotherapy plays an important role in patients with residual, recurrent, or unresectable craniopharyngiomas.

Common techniques include:

● Intensity-Modulated Radiation Therapy (IMRT)

● Stereotactic Radiosurgery (SRS)

● Proton therapy (available at selected centers)

Modern radiation therapy helps control tumor growth while minimizing radiation exposure to surrounding healthy brain tissue.

Treatment for Cystic Lesions

For predominantly cystic tumors, treatment options may include:

● Cyst aspiration

● Intracystic catheter placement

● Intracystic drug therapy (available at selected centers)

These approaches can relieve symptoms and serve as part of a comprehensive treatment plan.

Targeted Therapy

Recent advances in molecular biology have promoted the development of precision medicine for craniopharyngioma.

For patients with papillary craniopharyngioma harboring the BRAF V600E mutation, combination therapy with BRAF inhibitors and MEK inhibitors has become an important area of international research.

Clinical studies have shown that this treatment can significantly reduce tumor size in some patients, potentially making surgery less invasive or serving as an important treatment option for recurrent disease.

Long-Term Follow-up and Endocrine Management

Because craniopharyngioma carries a risk of recurrence, long-term follow-up is essential and typically includes:

● Regular MRI examinations

● Endocrine function monitoring

● Vision and visual field assessments

● Neurological evaluations

Some patients may require lifelong hormone replacement therapy to maintain normal metabolic function and quality of life.

What Are the Latest Advances in Craniopharyngioma Treatment?

In recent years, the management of craniopharyngioma has entered the era of precision medicine.

On the one hand, advances in neurosurgical techniques have made minimally invasive endoscopic endonasal surgery an important treatment option for selected patients.

On the other hand, high-precision radiotherapy has improved tumor control while reducing treatment-related side effects.

In addition, advances in molecular classification have led to the discovery of the BRAF V600E mutation, driving the development of targeted therapies.

International studies have demonstrated that BRAF/MEK combination therapy can significantly reduce tumor volume in patients with papillary craniopharyngioma, offering a promising treatment strategy for selected individuals.

As additional clinical research becomes available, precision medicine is expected to further improve long-term outcomes for patients with craniopharyngioma.

Conclusion

Although craniopharyngioma is generally considered a benign tumor, its location near critical brain structures means it can have lasting effects on vision, endocrine function, and neurological health. Early diagnosis and standardized treatment are therefore essential.

With ongoing advances in neurosurgery, precision radiotherapy, and molecular targeted therapy, the management of craniopharyngioma continues to evolve toward more precise, individualized, and multidisciplinary care, offering patients improved long-term survival and quality of life.

If you would like to learn more about craniopharyngioma treatment options or global pharmaceutical solutions, feel free to contact DengYueMed for professional healthcare information and international pharmaceutical support.